Bank of America
VRDN icon

Bank of America’s Viridian Therapeutics VRDN Stock Holding History

Bank of America’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.3M Sell
944,345
-219,270
-19% -$3.53M ﹤0.01% 2609
2026
Q1 		$22.8M Buy
1,163,615
+173,498
+18% +$5.15M ﹤0.01% 2275
2025
Q4 		$30.8M Buy
990,117
+744,358
+303% +$20.4M ﹤0.01% 1922
2025
Q3 		$5.3M Buy
245,759
+14,915
+6% +$269K ﹤0.01% 3942
2025
Q2 		$3.23M Buy
230,844
+50,721
+28% +$688K ﹤0.01% 4321
2025
Q1 		$2.43M Sell
180,123
-66,984
-27% -$1.14M ﹤0.01% 4506
2024
Q4 		$4.74M Buy
247,107
+66,138
+37% +$1.44M ﹤0.01% 3644
2024
Q3 		$4.12M Sell
180,969
-29,708
-14% -$486K ﹤0.01% 3925
2024
Q2 		$2.74M Sell
210,677
-265,056
-56% -$3.67M ﹤0.01% 4176
2024
Q1 		$8.33M Buy
475,733
+189,285
+66% +$3.67M ﹤0.01% 3158
2023
Q4 		$6.24M Buy
286,448
+81,225
+40% +$1.28M ﹤0.01% 3360
2023
Q3 		$3.15M Buy
205,223
+26,472
+15% +$505K ﹤0.01% 3830
2023
Q2 		$4.25M Sell
178,751
-76,070
-30% -$1.95M ﹤0.01% 3562
2023
Q1 		$6.48M Buy
254,821
+139,443
+121% +$4.47M ﹤0.01% 3271
2022
Q4 		$3.37M Buy
115,378
+58,682
+104% +$1.35M ﹤0.01% 3776
2022
Q3 		$1.16M Buy
56,696
+44,967
+383% +$808K ﹤0.01% 4763
2022
Q2 		$136K Sell
11,729
-6,104
-34% -$82K ﹤0.01% 6324
2022
Q1 		$330K Buy
17,833
+8,319
+87% +$160K ﹤0.01% 6115
2021
Q4 		$188K Buy
9,514
+9,341
+5,399% +$174K ﹤0.01% 6533
2021
Q3 		$3K Buy
+173
New +$2.54K ﹤0.01% 7843
2021
Q2 		– Sell
-16
Closed – – 8112
2021
Q1 		$0 Buy
+16
New +$300 ﹤0.01% 7811
2020
Q2 		– Hold
0
– – – 7151
2020
Q1 		– Hold
0
– – – 7272
2019
Q3 		– Sell
-1,286
Closed -$40K – 7528
2019
Q2 		$40K Sell
1,286
-226
-15% -$9.07K ﹤0.01% 6392
2019
Q1 		$63K Sell
1,512
-696
-32% -$31.5K ﹤0.01% 6107
2018
Q4 		$100K Buy
2,208
+584
+36% +$33.8K ﹤0.01% 5918
2018
Q3 		$136K Buy
1,624
+135
+9% +$12.7K ﹤0.01% 5715
2018
Q2 		$143K Sell
1,489
-18
-1% -$1.9K ﹤0.01% 5601
2018
Q1 		$158K Buy
1,507
+1,245
+475% +$135K ﹤0.01% 5500
2017
Q4 		$41K Buy
262
+223
+572% +$28.4K ﹤0.01% 6159
2017
Q3 		$5K Buy
+39
New +$6.56K ﹤0.01% 6743
2016
Q4 		– Hold
0
– – – 7335
2016
Q3 		– Hold
0
– – – 7378
2016
Q2 		– Hold
0
– – – 7404
2015
Q4 		– Sell
-277
Closed -$58K – 7483
2015
Q3 		$58K Buy
277
+61
+28% +$21.4K ﹤0.01% 5903
2015
Q2 		$106K Hold
216
– – ﹤0.01% 5561
2015
Q1 		$104K Buy
+216
New +$125K ﹤0.01% 5292

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Bank of America's VRDN Position: Q2 2026 in Review

Bank of America reduced its Viridian Therapeutics (VRDN) stake by 19% in Q2 2026, selling an estimated $3.53M and leaving 944,345 shares worth $17.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2609.

Bank of America first reported a position in VRDN in Q1 2015 and has held it in 32 quarters since. The position peaked at $30.8M in Q4 2025. 212 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Bank of America held 944,345 shares of Viridian Therapeutics worth $17.3M as of Q2 2026.
  • Bank of America sold 219,270 Viridian Therapeutics shares in Q2 2026, an estimated $3.53M.
  • Viridian Therapeutics made up ﹤0.01% of Bank of America's portfolio in Q2 2026, its #2609 holding.
  • Bank of America first reported a position in Viridian Therapeutics in Q1 2015 and has held it in 32 quarters since.
  • Bank of America's Viridian Therapeutics position peaked at $30.8M in Q4 2025.
  • 212 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Bank of America's 13F filing for Q2 2026, filed 14 Aug 2026.